Coherus BioSciences Inc
NASDAQ:CHRS

Watchlist Manager
Coherus BioSciences Inc Logo
Coherus BioSciences Inc
NASDAQ:CHRS
Watchlist
Price: 1.01 USD -5.61% Market Closed
Market Cap: 117.1m USD

Net Margin
Coherus BioSciences Inc

-66.3%
Current
-75%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-66.3%
=
Net Income
-130.9m
/
Revenue
197.5m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Coherus BioSciences Inc
NASDAQ:CHRS
117.1m USD
-66%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
337.7B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
163.2B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
142.2B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
133.2B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.4B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Coherus BioSciences Inc
Glance View

Market Cap
117.1m USD
Industry
Biotechnology

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. The company is headquartered in Redwood City, California and currently employs 332 full-time employees. The company went IPO on 2014-11-06. The firm is focused on the research, development and commercialization of immunotherapies to treat cancer. The company operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. The company is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.

CHRS Intrinsic Value
4.09 USD
Undervaluation 75%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-66.3%
=
Net Income
-130.9m
/
Revenue
197.5m
What is the Net Margin of Coherus BioSciences Inc?

Based on Coherus BioSciences Inc's most recent financial statements, the company has Net Margin of -66.3%.

Back to Top